Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain activ... Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. Show more
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1865 | -24.0335051546 | 0.776 | 0.799 | 0.54 | 56513 | 0.61273726 | CS |
4 | -0.0328 | -5.27076972521 | 0.6223 | 1.1099 | 0.54 | 732378 | 0.87910331 | CS |
12 | -0.3409 | -36.6401547721 | 0.9304 | 1.1099 | 0.5 | 244516 | 0.87585937 | CS |
26 | -1.0105 | -63.15625 | 1.6 | 1.87 | 0.5 | 120071 | 0.91413067 | CS |
52 | -1.1405 | -65.9248554913 | 1.73 | 1.98 | 0.5 | 66351 | 0.92519044 | CS |
156 | -7.2505 | -92.4808673469 | 7.84 | 9.4 | 0.5 | 64902 | 3.99205883 | CS |
260 | -14.3705 | -96.0594919786 | 14.96 | 19.56 | 0.5 | 350985 | 10.82668685 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.